Drug Profile

Research programme: immuno-oncology therapies - Evotec SE/Recursion Pharmaceuticals

Latest Information Update: 29 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evotec AG; Exscientia
Developer Evotec SE; Recursion Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action 5-nucleotidase inhibitors; Adenosine A2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals
28 Oct 2022 No recent reports of development identified for research development in Cancer in Germany
28 Oct 2022 No recent reports of development identified for research development in Cancer in United Kingdom

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com